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Abstract
OBJECTIVE: To explore the anticancer mechanism
of aqueous extract of Taxus Chinensis (Pilger) Rehd
(AETC).
METHODS: The serum pharmacological method
was used to avoid interference from administration
of the crude medicinal herbs. Eight purebred New
Zealand rabbits were used for preparation of serum
containing various concentrations of AETC. For-
ty-eight Balb/c-nu mice were used for in vivo experi-
ments. The effects of serum containing AETC on
the proliferation of A549 cells and expression levels
of the epidermal growth factor receptor/mito-
gen-activated protein kinase (EGFR/MAPK) path-
way-related proteins in vitro were investigated. Ad-
ditionally, the effects on the growth of A549 xeno-
grafts in nude mice, and expression levels of the EG-
FR/MAPK pathway-related proteins in the xeno-
grafts, were investigated.
RESULTS: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) assay revealed that the
serum containing AETC significantly decreased the
viability of A549 cells in a dose-dependent manner.
Western blot showed that the serum containing
various concentrations of AETC strongly reduced
the levels of phospho-Jun N-terminal kinase
(p-JNK) and phospho-extracellular signal-regulated
kinase1/2 (ERK1/2) while it increased the level of
p-p38. However, no significant effects on the ex-
pression levels of JNK, ERK1/2, and p38 MAPK were
found. In addition, an anticancer effect from AETC
was observed in vivo in the Balb/c-nu mice bearing
A549 xenografts.
CONCLUSION: AETC has significant effects on the
growth of A549 xenografts and on the activity of
the EGFR/MAPK pathway. Therefore, AETC may be
beneficial in lung carcinoma treatment.
© 2014 JTCM. All rights reserved.
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INTRODUCTION
Lung cancer is the leading cause of death in cancer pa-
tients worldwide,1 and non-small-cell lung cancer
(NSCLC) accounts for more than 75% 2 of lung can-
cers. With only a 20%-35% response rate and a medi-
an survival of 10-12 months, chemotherapy is still not
effective enough for patients with advanced NSCLC.3,4
Therefore, targeting molecules are critical to cancer
treatment and targeted therapy alone or in combina-
tion with other therapies is a promising strategy for
treating cancers including NSCLC.5 Moreover, the use
of complementary and alternative medicine (CAM) to
relieve the side effects and improve the efficacy of che-
motherapy is popular for treating cancer patients, par-
ticularly in Western countries.6 Traditional Chinese
medicine (TCM) has a long history of treating diseases
with advantages of low costs, multiple targets, and low
toxicity. Therefore, TCM has been extensively used as
an alternative medicine in many countries.
Taxus, a general term for Taxaceae Taxus species, is a
natural anticancer plant. Taxus Chinensis (Pilger) Rehd
is one of the subspecies of Taxus. A variety of extracts
from Taxus Chinensis (Pilger) Rehd have been used as
the anticancer compounds, such as paclitaxel, cephalo-
mannine, baccatin Ⅲ, 10-deacetyl baccatin Ⅲ, and
polyprenols.7-10 Paclitaxel is the most effective antican-
cer ingredient extracted from Taxus species. According
to our previous study, the aqueous extract of Taxus Chi-
nensis (Pilger) Rehd (AETC) inhibits A549 cells by in-
ducing apoptosis while paclitaxel induces cellular necro-
sis.11 Therefore, the active ingredient of AETC is not
paclitaxel.
AETC has been used as a TCM formula for thousand
years in China. It is bitter in flavor and nature with tro-
pism to the heart meridian. AETC is usually used to
treat cancer, kidney disease, and rheumatism alone or
in combination with other herbs. Our previous studies
have shown that AETC has inhibitory effects on A549
cells and induces cell cycle arrest and apoptosis.12 How-
ever, the underlying molecular mechanism has not
been investigated. Therefore, the present study is de-
signed to elucidate the possible mechanism of cell
apoptosis induced by AETC.
We investigated whether serum containing AETC in-
hibited the viability of A549 cells or down-regulated
epidermal growth factor receptor/mitogen-activated
protein kinase (EGFR/MAPK) signaling in vitro. In
the in vivo experiments, we explored whether AETC
exhibited significant inhibitory effects on the growth
of A549 xenografts and on the activity of the EGFR/
MAPK pathway.
MATERIALS ANDMETHODS
Materials
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-
bromide (MTT), penicillin, and streptomycin were
purchased from Sigma (St. Louis, MO, USA). F12-K
medium, fetal bovine serum, and trypsin-EDTA (Eth-
ylene Diamine Tetraacetic Acid) were purchased from
Gibco BRL (Gaithersburg, MD, USA). Antibodies
against epidermal growth factor receptor (EGFR),
phospho-EGFR (p-EGFR), extracellular signal-regulat-
ed protein kinases (ERK1/2), phospho-ERK1/2
(p-ERK1/2), c-Jun N-terminal kinase (JNK), phos-
pho-JNK (p-JNK), p38, and phospho-p38 (p-p38)
were purchased from Cell Signaling Technologies (Bev-
erly, MA, USA). Antibodies against β-tubulin were ob-
tained from Sigma. Horseradish Peroxidase (HRP)-con-
jugated secondary antibodies against mouse IgG and
rabbit IgG were purchased from Santa Cruz Biotech-
nology, Inc. (Santa Cruz, CA, USA). Enhanced Chemi-
luminescent Kits (ECK) were obtained from Millipore
Corporation (Billerica, MA, USA).
Taxus chinensis (Pilger) Rehd (8 g/bag) was purchased
from the Pharmacy of Zhejiang Provincial Hospital of
Traditional Chinese Medicine, produced by Ningbo
Taikang Bio-engineering Company (Ningbo, China).
The main ingredient of this product is the powder of
Taxus Chinensis (Pilger) Rehd tree bark. Taxus Chinensis
(Pilger) Rehd is prepared into an aqueous extract and
administered orally during TCM anticancer therapy.
To evaluate the anti-tumor effects of Taxus Chinensis
(Pilger) Rehd, the preparation of AETC used in this
study was based on the TCM processing method.
Dry Taxus Chinensis (Pilger) Rehd was immersed three
times in distilled water for 30 min. This raw solution
was boiled for 30 min, then concentrated to 208 mg/
mL. The undiluted solution was used as the high dos-
age for the animal experiment, and the 1∶2 and 1∶4 di-
luted solutions were used for the medium and low dos-
ages, respectively. Samples were stored at﹣4℃ for use.
Animals
Purebred New Zealand rabbits and Balb/c-nu mice
were obtained from Hercynian poole-Rubicam Experi-
mental Animals Co., Ltd. (production license number:
SCXK, Shanghai, China, 2008-0016). All the animal
experiments in this study were carried out in Zhejiang
University of Traditional Chinese Medicine and ap-
proved by the Animal Ethics Committee. All animals
were housed under controlled conditions (23℃ , hu-
midity 70%, 12 h light and 12 h dark) for 4 days be-
fore the experiment. Eight purebred New Zealand rab-
bits were used for preparation of the serum containing
various concentrations of AETC. Forty-eight Balb/
c-nu mice aged 5-6 weeks were used for the in vivo ex-
periments. Nude mice were kept in a temperature-con-
trolled and specific pathogen free (SPF) room of the ex-
perimental animal center.
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Preparation of the serum containing AETC
Eight male purebred New Zealand rabbits, weighing
about 2000 g, were randomly divided into four groups
by random number method (2 rabbits per group). Ac-
cording to the formula of the equivalent dose of direct
conversion:13 drabbit (mg/kg)=drabbit×Rrabbit(Whuman)1/3/Rhuman×
Wrabbit; where drabbit is the dose for New Zealand rabbit
(mg/kg), dhuman is the dose for human (mg/kg); Whuman is
the bodyweight for humans in general; andWhuman=70 kg,
Wrabbit=2 kg, Rhuman=0.1, Rrabbit=0.093. The four groups
were all treated by gavageThe low dosage was half the
medium while the high dosage was two times the medi-
um. The control group was treated with 10 mL dis-
tilled water by gavage. The low-dose group was treated
with AETC at 186.65 mg·kg﹣1·d﹣1. The medium-doge
group was treated with AETC at 373.3 mg·kg﹣1·d﹣1.
The high-dose group was treated with AETC at
746.6 mg·kg ﹣ 1·d ﹣ 1. All rabbits were administered
AETC intragastrically for 7 consecutive days. The rab-
bits' blood serum was taken via cardiac puncture 1 h af-
ter the last administration. The sera of each group were
mixed and placed at 56℃ for 30 min to inactivate the
complement, then filtered through a 0.22 μm micro-
pore filtrate for sterilization and kept at ﹣20℃ until
use.
Cell line and culture conditions
A549 human lung carcinoma cells obtained from
Shanghai Institute of Cell Biology (Academia Sinica,
Shanghai, China) were cultured in F12-K medium
(Gibco, Gaithersburg, MD, USA) supplemented with
10% HyClone fetal bovine serum (Thermo company,
Waltham, MA, USA) and 1% penicillin/streptomycin
in a 5% CO2 atmosphere at 37℃. When the cells grew
to 70%-80% confluency, the control group was given
serum, while the other groups were given 10% serum
containingAETC for 24 h in complete growthmedium.
Cell viability assay
Cytotoxicity of the serum containing AETC in A549
cells was investigated using the standard MTT assay.
A549 cells were seeded in a 96-well plate (Nest Biotech
Co. Ltd., Shanghai, China)(200 μ\L/well) and incubat-
ed for 24 h at 37℃. The cells were treated with serum
from the control group or treated with 10% serum con-
taining various concentrations of AETC for 24 h at
37℃ . Then, 20 μL of 5 mg/mL MTT in PBS (Keyi
Biotech Co., Ltd., Hangzhou, China) were added to
each well and incubated for 4 h at 37℃. The superna-
tant was removed after centrifugation. Finally, 150 μL
of dimethyl sulfoxide (Sigma, St. Louis, MO, USA)
was added with absorbance at 490 nm. Wavelength
(A490) was measured by an ELX808 Micro Plate Read-
er (Bio-Tek Instruments Inc., Winooski, VT, USA).
Relative cell proliferation inhibition rate (IR)=(1－aver-
age A490 of the treatment group/average A490 of the
control group)×100%. The experiments were indepen-
dently repeated three times.
Protein extraction and western blot analysis
105 exponentially growing A549 cells were cultured in
a 6-well plate (Nest Biotech Co., Ltd., Shanghai, Chi-
na). Cells were incubated in 10% serum from the con-
trol group or 10% serum containing various concentra-
tions of AETC for 24 h at 37℃ in an atmosphere con-
taining 5% CO2. After washing with ice-cold PBS, the
cells were lysed in RIPA lysis buffer (Roche, Basel, Swit-
zerland) containing a protease inhibitor cocktail. The
extracts were centrifuged at 12 000 r/min for 5 min at
4℃ to remove debris, and the protein concentration was
determined using a Bradford assay (Bio-Rad, Hercules,
CA, USA). The extracted protein samples (30 μg total
protein/lane) were added in five volumes of sample buf-
fer and subjected to denaturation at 100℃ for 10 min.
Then, the proteins were separated by 10% SDS-poly-
acrylamide gel electrophoresis at 250 mA for 2.5 h,
and transferred onto a polyvinylidene fluoride (PVDF)
membrane (Immunobilon-P, 0.45 mm; Millipore Co.,
Billerica, MA, USA). The membranes were blocked
with 5% skim milk in Tris-buffered saline containing
1% Tween 20 (TBS-T, pH 7.4) at room temperature
for 1 h, followed by incubation with primary antibodies
(Cell Signaling Technologies, Beverly, MA, USA) (dilu-
tion 1∶3000) at 37℃ for 1.5 h or at 4℃ overnight.
The membranes were washed three times with TBS-T
for 10 min each at room temperature and incubated
with a 1∶2000 dilution of HRP-conjugated secondary
antibody for 2 h at room temperature. The membranes
were then rewashed three times with TBS-T. The pro-
teins were visualized using ECL and MP4 + Chemi-
docXRS protein mark detection system (Bio-Rad Labo-
ratories, Inc., Hercules, CA, USA). β-tubulin was used
as the internal loading control. The densitometry read-
ings of the bands were normalized to β-tubulin expres-
sion. The band intensity was analyzed using Quantity
One software (Bio-Rad Laboratories, Inc., Hercules,
CA, USA).
In vivo experiment
0.2 mL A549 cells (107 cells/mL) were subcutaneously
injected into the nape of nude mice. After inoculation,
48 Balb/c-nu mice bearing A549 xenografts were ran-
domly divided into four groups by random number
method (24 rats per group). The treatments were: con-
trol group treated with 10ml physiological saline;
low-dose group treated with AETC (0.52 mg·g﹣1·d﹣1);
medium-dose group treated with AETC (1.04 mg·g﹣1·
d﹣1); and high-dose group treatedwith AETC (2.08 mg·
g﹣1·d﹣1). The medium dosage was calculated according
to the human and animal body surface area conversion
method. The low dosage was half the medium while
the high dosage was two times the medium. After 24 h,
different treatments were given once a day via gastric
gavage. The length and width of the xenografts were
measured by vernier calipers every 3 days during the
course of treatment. The volume of the xenografts was
calculated by the standard formula,14 and the xenograft
295
JTCM |www. journaltcm. com June 15, 2014 |Volume 34 | Issue 3 |
Shu QJ et al. / Experimental Study
growth curves were plotted. The standard formula was
volume=a × b2/2 (a stands for length, and b indicates
width). The above treatments were given for 7 weeks.
All mice were sacrificed 24 h after the last administra-
tion. The weight of the primary subcutaneous xeno-
graft and the inhibitory rate of the weight were then ex-
amined. The xenografts were stripped and stored in liq-
uid nitrogen. 20 mg of the tumor tissues were cut
down and washed three times with distilled water. The
methods for protein extraction and western blot analy-
sis were the same with the cell experiments. Western
blot was used to detect the expression levels of EGFR,
p-EGFR, JNK, p-JNK, p-ERK, p8MAPK, and
p-p38MAPK in xenografts.
Statistical analysis
All the data are expressed as mean±standard deviation
(SD). The statistical analyses were performed using
SPSS 17.0 software (Chicago, IL, USA). Compari-
sons were made between each of the treatment
groups and the control group by one-way ANOVA,
and a difference of P<0.05 was considered to be sta-
tistically significant.
RESULTS
Effects of serum containing AETC on the
proliferation of A549 cells
In the present study, after 24 h adherence, the A549
cells in the control group and the treatment groups
were treated with 10% serum and 10% serum contain-
ing various concentrations of AETC, respectively. As
shown in Table 1, the serum containing AETC marked-
ly inhibited the proliferation of A549 cells in a dose-de-
pendent manner, and the optical density in the treat-
ment groups was significantly lower than that in the
control group. Therefore, the proliferation of A549
cells is attenuated by serum containing AETC.
Effects of serum containing AETC on expression
levels of the EGFR/MAPK pathway-related proteins
in vitro
To determine the effects of serum containing AETC
on the EGFR/MAPK pathway, the expression levels of
ERK1/2, p-ERK1/2, JNK, p-JNK, p38MAPK, and
p-p38MAPK were detected by western blot 24 h after
A549 cells were treated with serum containing various
concentrations of AETC. As shown in Figure 1, the lev-
el of p-p38MAPK expression in the treatment groups
was significantly higher than that in the control group.
Moreover, the expression levels of p-ERK1/2 and
p-JNK in the treatment groups were lower than those
in the control group. However, no significant changes
in the expressions of ERK1/2, JNK, and p38MAPK
were found. The levels of ERK, JNK, and p38 did not
significantly change (P>0.05). The levels of PERK and
PJNK were significantly lower (P<0.05), and the level
of Pp38 was significantly higher than that in the con-
trol group (P<0.05) (Figure 1).
Effects of AETC on the growth of A549 xenografts in
nude mice
The inhibitory effect of AETC on A549 cells in vitro
suggested that it might suppress the tumor growth in
vivo. To confirm this hypothesis, animal experiments
were performed. Twenty-four hours after the inocula-
tion, different treatments were given once daily. The xe-
nografts were palpable 5 days later. Inoculating A549
cells subcutaneously to establish the A549 xenograft
model in nude mice was successful and the tumor for-
mation rate was 100%. Two weeks later, the length and
width of the xenografts were measured every 3 days
during the course of treatment. The volume of the xe-
nograft was calculated by the standard formula and the
xenograft growth curves were plotted. As shown in Ta-
ble 2 and Figure 2, the growth rate of the treatment
groups was slower than that in the control group. Sev-
en weeks after the treatment, the weight of the primary
subcutaneous xenograft and the inhibitory rate of the
weight were examined 24 h after the last administra-
tion, when all the mice were sacrificed. As shown in Ta-
ble 3, different dosage of AETC exhibited a significant
anti-tumor effect compared with the control group (P<
0.01). The inhibitory rates were 47.53%, 39.59%, and
46.47% in the low-dose, medium-dose, and high-dose
AETC groups, respectively.
Effects of AETC on expression levels of the EGFR/
MAPK pathway-related proteins in xenografts
To further confirm the effect of AETC on expression
of the EGFR/MAPK pathway, we used western blot
analysis to detect the level of EGFR, p-EGFR, ERK1/
2, p-ERK1/2, JNK, p-JNK, p38MAPK, and
p-p38MAPK in xenografts. Compared with the con-
trol group, densitometry showed that the levels of EG-
FR, ERK, JNK, and p38 were not significantly differ-
ent (P>0.05), the levels of p-EGFR, p-ERK, and
p-JNK were significantly lower (P<0.05), and the level
Group
Control
Low-dose
Medium-dose
High-dose
n
3
3
3
3
Absorbance
1.139333
0.914333
0.769333
0.658000
Inhibitory
rate (%)
-
19.73a
32.46b
42.23b
Table 1 MTT Results among different groups
Notes: the control group was treated with 10 mL distilled wa-
ter by gavage. The low-, medium- and high-dose group were
treated with AETC at 186.65, 373.3, and 746.6 mg·kg﹣1·d﹣1 re-
spectively. AETC were administered intragastrically for 7 con-
secutive days. MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide; AETC: aqueous extract of Taxus chinen-
sis (Pilger) Rehd. Compared with the control group, aP<0.05,
bP<0.01.
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of p-p38 was significantly higher (P<0.05) than that in
the control group (Figure 3). Therefore, the activities
of EGFR and ERK1/2 were possibly decreased while
that of p38 increased in the xenografts. Additionally,
AETC might inhibit A549 xenograft growth by sup-
pressing the EGFR/MAPK pathway.
DISCUSSION
Taxus chinensis (Pilger) Rehd is an evergreen tree distrib-
uted in the southeastern region of China. Research in-
to Taxus species has increased since the isolation of pa-
clitaxel (Taxol) from the short yew (Taxus brevifolia) in
1971,15 which has a diterpenoid structure and strong
anticancer effects. Our previous study demonstrated
that AETC may inhibit the proliferation of A549 cells
and induce G0/G1 phase cell cycle arrest and apopto-
sis. The growth curve assay showed that AETC inhibit-
ed the proliferation of A549 cells in dose- and time-de-
pendent manners.12 The inhibitory effect of serum con-
taining AETC on the proliferation of A549 cells is of
great value for exploring the related signaling pathways.
Serum pharmacological research on compound herbal
recipes has been performed for many years.16,17 This
method involves removing the serum from animals ad-
ministrated certain herbal medicine solutions intragas-
trically. The serum can better reflect real pharmacologi-
cal effects of the drug in vivo, avoiding interference
and simulating in vivo conditions from the crude me-
dicinal herbs after administration. Within a certain
range, the drug concentration in serum changes with
the drug dosage administrated to the animal. There-
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Figure 1 Effects of AETC on the expression of the EGFR/MAPK pathway-related proteins
1: the control group, was treated with 10 mL distilled water by gavage; 2: the low-dose group; 3: the medium-dose group; 4: the
high-dose group. A: ERK1/2; B: p-ERK1/2; C: JNK; D: p-JNK; E: p38; F: p-p38. The control group was treated with 10 mL distilled wa-
ter by gavage; the low-, medium- and high-dose group was treated with AETC at 186.65, 373.3, and 746.6 mg·kg﹣1·d﹣1 respec-
tively. AETC: aqueous extract of Taxus Chinensis (Pilger) Rehd; EGFR/MAPK: epidermal growth factor receptor/mitogen-activated
protein kinase; ERK1/2: extracellular signal-regulated protein kinases; p-ERK1/2: phospho-ERK1/2; JNK: c-Jun N-terminal kinase;
p-JNK: phospho-JNK; p-p38: phospho-p38. aP<0.05; bP<0.01, Compared with the control group.
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fore, we used the serum pharmacological method to ex-
plore the efficacy of AETC on A549 cells in vivo.
The epidermal growth factor receptor (EGFR) is a
transmembrane glycoprotein with a molecular weight
of 170 kDa. It can interact with ligands, activate the
downstream system, regulate cell proliferation, surviv-
al, adhesion, migration, differentiation, and promote
wound healing.18 EGFR can also induce angiogenesis
and stop apoptosis.19 The expression level of EGFR is
higher in malignant tissues than that in normal tissues.
It is reported that over-expression of EGFR is present
in 40%-80% non-small-cell lung cancer (NSCLC) pa-
tients.20,21 Therefore, blocking or attenuating the EGFR
signaling pathway is a promising strategy for control-
ling cancers including NSCLC.
Receptor down-regulation is the most prominent regu-
lating way for EGFR signal attenuation, which in-
volves the internalization and subsequent degradation
of the activated receptor in the lysosomes.22 EGFR has
six autophosphorylation sites (Y992, Y1045, Y1068,
Y1086, Y1148, and Y1173) for regulating the activity
of EGFR. It has been reported that Y1068 and Y1148
are the major autophosphorylation sites, while Y992,
Y1045, and Y1086 are in the minority.23-25 The auto-
phosphorylation site Y1068 is related to EGFR/
MAPK. Interestingly, our in vivo study showed that
AETC exhibited no significant influence on the degra-
Figure 2 Effects of AETC on the growth of A549 xenografts
The xenograft growth curves were plotted. A: the control group was treated with 10 mL distilled water by gavage; B: the low-dose
group; C: the medium-dose group; D: the high-dose group. B, C, D, groups were treated with AETC at 186.65, 373.3, and 746.6 mg·
kg﹣1·d﹣1 respectively. AETC: aqueous extract of Taxus Chinensis (Pilger) Rehd.
3
Day
14
17
20
23
26
29
32
35
38
41
44
47
49
A
24±12
31±28
51±19
97±30
134±53
200±67
276±61
438±95
533±48
631±57
841±54
956±49
1473±76
B
25±13
38±21
59±21
73±44
99±58
151±20
224±61
302±59
473±82
515±58
605±55
598±43
851±89
C
25±17
41±22
54±22
67±43
92±15
156±76
219±64
283±34
370±51
425±48
489±93
606±37
969±58
D
21±7
42±19
57±21
72±38
95±26
113±42
195±56
276±48
382±67
440±40
494±32
596±23
859±64
Table 2 Effects of AETC on the growth of A549 xenografts
( xˉ ±s, n=12)
Notes: A: the control group was treated with 10 mL distilled wa-
ter by gavage. B: the low-dose group; C: the medium-dose
group; D: the high-dose group. B, C, D groups were treated
with AETC at 186.65, 373.3, and 746.6 mg·kg﹣1·d﹣1 respec-
tively. AETC: aqueous extract of Taxus Chinensis (Pilger) Rehd.
Group
A
B
C
D
Weight of xenografts
113±12
60±7a
68±10a
61±10a
Inhibitory rate (%)
-
47.53
39.59
46.47
Table 3 Effects of AETC on the growth of A549 xenografts
( xˉ ±s, n=12)
Notes: the weight of the primary subcutaneous xenografts and
the inhibitory rate of the weight were examined 24 h after the
last administration, when all the mice were sacrificed. A: the con-
trol group was treated with 10 mL distilled water by gavage. B:
the low-dose group; C: the medium-dose group; D: the
high-dose group. B, C, D group were treated with AETC at
186.65, 373.3, and 746.6 mg·kg﹣ 1·d﹣ 1 respectively. aP<0.05,
compared with the control group. AETC: aqueous extract of
Taxus Chinensis (Pilger) Rehd.
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dation of EGFR, but it significantly suppressed pr-EG-
FR (Y1068).
AETC can decrease the p-EGFR to attenuate the EG-
FR signaling pathway, inhibit cell proliferation, adhe-
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Figure 3 Effects of AETC on expression of the EGFR/MAPK pathway-related proteins in A549 xenografts
1: the control group was treated with 10 mL distilled water by gavage; 2: the low-dose group; 3: the medium-dose group; 4: the
high-dose group. A; EGFR; B: p-EGFR; C: JNK; D: p-JNK; E: p38; F: p-p38; G: ERK1/2; H: p-ERK1/2. The control group was treated with
10 mL distilled water by gavage; the low-, medium- and high-dose group was treated with AETC at 186.65, 373.3, and 746.6 mg·
kg﹣1·d﹣1 respectively. AETC: aqueous extract of Taxus Chinensis (Pilger) Rehd; EGFR/MAPK: epidermal growth factor receptor/mito-
gen-activated protein kinase; EGFR: epidermal growth factor receptor; p-EGFR: phospho-EGFR; JNK: c-Jun N-terminal kinase;
p-JNK: phospho-JNK; p-p38: phospho-p38; ERK1/2: extracellular signal-regulated protein kinases; p-ERK1/2: phospho-ERK1/2.
Compared with the control group, aP<0.05; bP<0.01.
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sion, migration, angiogenesis, and induce apoptosis. To
explore the detailed mechanism, further in vitro studies
have been performed to investigate the effect of AETC
on the EGFR downstream pathway in vitro and in vivo.
The mitogen-activated protein kinase (MAPK) path-
way is one of the main downstream effectors of EGFR,
including the ERK1/2, the JNK/stress-activated pro-
tein kinase, and p38 MAPK.26,27 A number of studies
have demonstrated that the EGFR/MAPK pathway is
responsible for proliferation, survival, and metastasis of
cancer cells,28,29 suggesting that identifying the ap-
proaches or drugs for inhibiting this pathway might
have potential therapeutic value. To identify the signal-
ing pathway (s) involved in the underlying mechanism,
the phosphorylation/activation of cancer-related
MAPKs including p38, JNK, and ERK1/2 in A549
lung cancer cells should be detected.
JNK regulates many cellular processes, including cell
proliferation, differentiation, survival, and migration.
To date, thousands of papers have been published to di-
rectly or indirectly address the function of JNK in tis-
sue homeostasis, cellular metabolism, inflammation,
and carcinogenesis. JNK is activated in a subset of
NSCLC biopsy samples and it promotes oncogenesis
in bronchial epithelium.30 Moreover, the JNK pathway
can stimulate NSCLC cell proliferation to cooperate
with the PI3K pathway for maintaining cell survival.31
The p38 MAPK signaling pathway has a negative regu-
latory function26 for its inhibitory effect on cell prolifer-
ation and tumorigenesis.32 ERK1/2 is also a crucial
molecule in cell proliferation and carcinogenesis. It is
activated by dual phosphorylation on both Thr202
and Tyr204 residues. The activated ERK1/2 has been
reported in a variety of human tumor cell lines33 and
epithelial cancer tissues including small- and
non-small-cell lung cancers.34
According to our study, neither in vitro nor in vivo ex-
pression levels of cancer-related MAPKs (JNK, p38,
and ERK1/2) changed significantly after AETC admin-
istration. At the same time, we found that p-p38 in-
creased significantly while p-JNK and p-ERK1/2 signif-
icantly decreased.
According to the previous report, p38 antagonizing the
JNK-c-Jun pathway is a possible mechanism for sup-
pressing tumorigenesis.35 However, how AETC sup-
presses the expression of p-JNK and p-ERK1/2 re-
mains unclear. In the present study, we assume that the
enhanced p-p38 is a down-regulation factor for p-JNK
and p-ERK1/2.
The in vivo anticancer assay revealed that AETC effec-
tively inhibited the growth of A549 xenografts, and the
experimental results showed that the anticancer effects
of AETC on A549 xenografts might be associated with
the down-regulation of the EGFR/MAPK pathway.
So far, we have only examined the Ras-raf-MAPK arm
of EGFR signaling. However, there are several other
signaling pathways known to be activated by EGFR, in-
cluding the phosphatidylinositol-3-kinase and Janus ki-
nase-signal transducers and activators of transcription
pathways,36 which need to be further detected.
Many of the chemotherapeutic agents for cancer treat-
ment have side effects. Traditional Chinese medicines
can be effective while avoiding adverse side effects.
However, in most circumstances, neither the chemical
entity nor the molecular mechanisms of action are well
defined. Taxus chinensis (Pilger) Rehd is such a medici-
nal plant used traditionally as an anticancer material.
The present study has demonstrated that serum con-
taining AETC inhibits the proliferation of A549 cells
in vitro and inhibits the growth of A549 xenografts in
vivo by suppressing the EGFR/MAPK signaling path-
way. This is the first study elucidating the anticancer
mechanism of AETC. Based on these results, we be-
lieve that AETC may be a potential anticancer agent to
be used worldwide.
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